Université de Montréal

Migration, Crosslink

📖

Université de Montréal

active

wiki page Created: 2026-04-02T07:20:10 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-institutions-university-of-montreal

📖 Wiki Page

institution2497 wordssynced 2026-04-02

Introduction

Université De Montréal is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-institution"> [@fon2017]
<div class="infobox-header">Université de Montréal</div> [@kim2018]
<div class="infobox-row"><strong>Location:</strong> Montreal, Quebec, Canada</div> [@weissmann2020]
<div class="infobox-row"><strong>Type:</strong> Public Research University</div>
<div class="infobox-row"><strong>Founded:</strong> 1878</div>
<div class="infobox-row"><strong>Website:</strong> [umontreal.ca](https://www.umontreal.ca)</div>
</div>

Overview

...

Introduction

Université De Montréal is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-institution"> [@fon2017]
<div class="infobox-header">Université de Montréal</div> [@kim2018]
<div class="infobox-row"><strong>Location:</strong> Montreal, Quebec, Canada</div> [@weissmann2020]
<div class="infobox-row"><strong>Type:</strong> Public Research University</div>
<div class="infobox-row"><strong>Founded:</strong> 1878</div>
<div class="infobox-row"><strong>Website:</strong> [umontreal.ca](https://www.umontreal.ca)</div>
</div>

Overview

Mermaid diagram (expand to render)

The Université de Montréal (UdeM) is one of Canada's largest public research universities, located in Montreal, Quebec. The university's Faculty of Medicine is one of the leading centers for neuroscience research in North America, with particular strength in neurodegenerative disease research, especially Alzheimer's disease and Parkinson's disease.

McGill University Collaboration

The Université de Montréal works closely with McGill University through the McGill-UdeM Neuroscience Partnership, which coordinates research efforts and shared facilities between the two institutionsations

U.

International CollabordeM maintains research partnerships with:

University of Oxford (UK)
University College London (UK)
Harvard Medical School (USA)
NIH/NIA (USA)
Pasteur Institute (France)

Training Programs

The university offers comprehensive training in neurodegenerative disease research:

PhD program in Neuroscience
Postdoctoral fellowship program
Clinical research training for neurologists
Summer school in Neurodegeneration

Disease Focus

| Disease | Research Intensity | Key Programs |
|---------|-------------------|--------------|
| Alzheimer's Disease | High | Biomarkers, clinical trials, basic mechanisms |
| Parkinson's Disease | High | DBS, Lewy body pathology, dopamine signaling |
| ALS | Moderate | Clinical trials, genetic studies |
| Prion Disease | High | Prion mechanisms, CJD diagnostics |
| Frontotemporal Dementia | Moderate | Tauopathies, genetic forms |

Future Directions

Current strategic initiatives include:

Development of novel biomarkers for early detection
Expansion of clinical trial capacity
Integration of AI and machine learning in neuroimaging analysis
Development of gene therapy approaches for neurodegenerative diseases

Montreal's Role in Global Neuroscience

Historical Significance

Montreal has been a global hub for neuroscience research since the founding of the Montreal Neurological Institute in 1934. The city's contributions to understanding brain function have been recognized worldwide, with Montreal hosting the Society for Neuroscience meeting in 2019 and continuing to attract international conferences and researchers. This historical legacy shapes current research directions at the Université de Montréal and its affiliated institutions[@montreal2024].

The city's unique position as a bilingual (French-English) research center provides access to diverse patient populations and facilitates international collaborations across both European and North American research networks. Quebec's distinctive healthcare system and research funding mechanisms have enabled the development of robust clinical research infrastructure that complements basic science programs[@crchum2024].

Quebec Neurodegeneration Research Network

Université de Montréal serves as the anchor institution for the Quebec Neurodegeneration Research Network, a provincial initiative that coordinates research efforts across universities, hospitals, and research institutes throughout Quebec. This network enables:

Shared patient registries and biobanks
Coordinated clinical trial recruitment
Joint training programs and symposia
Collaborative grant applications to federal and provincial agencies

The network leverages Quebec's universal healthcare system to enable population-based studies of neurodegenerative disease incidence, prevalence, and risk factors. Large-scale genomic studies conducted through the network have identified novel genetic risk factors specific to French-Canadian populations.

Montreal Neurological Institute and Hospital (The Neuro)

Research Programs

The Montreal Neurological Institute and Hospital (known as "The Neuro") represents one of the world's premier neuroscience centers. Founded by Dr. Wilder Penfield in 1934, The Neuro has pioneered advances in epilepsy surgery, brain mapping, and more recently, neurodegenerative disease research. The institute operates as a joint venture between McGill University and the Université de Montréal, creating a unique bilingual, binational research environment[leblanc2021].

Alzheimer's Disease and Related Dementias Program:
The program investigates fundamental mechanisms of Alzheimer's disease with particular emphasis on the role of caspase-6 in synaptic dysfunction and neuronal loss. Dr. Andréa LeBlanc's laboratory has demonstrated that caspase-6 activation occurs early in Alzheimer's disease progression, preceding clinical symptoms and representing a potential therapeutic target. The program also investigates neuroinflammation, focusing on microglial activation states and their contributions to disease progression[fon2020].

Parkinson's Disease and Movement Disorders Program:
Led by Dr. Edward Fon, the movement disorders program examines genetic determinants of Parkinson's disease, including LRRK2, PARK2 (parkin), PINK1, and GBA variants. The program has characterized the phenotypic consequences of different genetic mutations, enabling more precise diagnosis and potentially personalized treatment approaches. Deep brain stimulation research optimizes targeting and stimulation parameters for improved motor outcomes.

Prion Disease and Protein Misfolding Disorders Program:
Through affiliation with Dr. Charles Weissmann's laboratory, the institute maintains expertise in prion disease research, building on Canada's historical leadership in this field. Research programs examine prion strain diversity, transmission mechanisms, and diagnostic biomarkers. The program benefits from access to the Canadian CJD surveillance system, enabling rapid case identification and sample collection.

Clinical Services

The Montreal Neurological Hospital provides comprehensive neurological care through:

Memory clinic with specialized dementia diagnostics
Movement disorders clinic for Parkinson's disease and related conditions
Epilepsy monitoring unit
Multiple sclerosis treatment center
ALS multidisciplinary care program

Centre Hospitalier de l'Université de Montréal (CHUM) Research Centre

CRCHUM Research Programs

The Centre de Recherche du CHUM (CRCHUM) represents one of Canada's largest hospital-based research centers, with over 1,000 researchers and research personnel. The neuroscience research division maintains particular strength in neurodegenerative disease research, combining basic science laboratories with clinical research facilities[@crchum2024].

Translational Neuroscience Program:
This program bridges fundamental discoveries and clinical applications through:

Biomarker validation and clinical assay development
Drug target validation in patient-derived models
First-in-human clinical trial design and execution
Regulatory affairs support for clinical translation

Neuroimaging Research:
CRCHUM houses advanced neuroimaging capabilities including:

3T and 7T MRI scanners dedicated to research
PET imaging suite for amyloid, tau, and synaptic vesicle protein ligands
Advanced analysis pipelines for structural and functional MRI
Integration with clinical imaging systems for longitudinal studies

Clinical Trials Infrastructure:
The clinical trials unit coordinates industry-sponsored and investigator-initiated trials across neurodegenerative disease indications. The unit maintains:

Dedicated Phase I and II clinical trial facilities
Experienced clinical research coordinators
Electronic data capture systems
Sample processing and biobanking capabilities

Key Research Laboratories

LeBlanc Laboratory - Alzheimer's Disease Research

Dr. Andréa LeBlanc's laboratory investigates molecular mechanisms of Alzheimer's disease with particular focus on:

Caspase-6 activation in neuronal dysfunction
Synaptic protein cleavage and loss
Neuronal vulnerability in aging and disease
Development of caspase-6 inhibitors as therapeutics

The laboratory employs molecular biology, cellular biology, and mouse model approaches to understand how caspase-6 contributes to cognitive decline. Recent work has demonstrated that caspase-6 cleaves synaptic proteins important for memory formation, providing a mechanistic link between molecular pathology and functional deficits[leblanc2021].

Fon Laboratory - Movement Disorders

Dr. Edward Fon's laboratory focuses on:

Genetic determinants of Parkinson's disease
LRRK2 biology and kinase inhibitor development
Mitochondrial dysfunction in neurodegeneration
Parkin and PINK1 function in dopaminergic neurons

The laboratory has characterized LRRK2 mutations in Canadian patient cohorts, identifying both common and rare variants associated with disease risk. Current research examines LRRK2 kinase activity in patient-derived cells and develops biomarkers to monitor target engagement[fon2020].

Neuroimaging Laboratory

The neuroimaging group develops and applies advanced MRI and PET techniques for neurodegenerative disease research:

Structural MRI for atrophy measurement
Diffusion imaging for white matter integrity
Resting-state fMRI for functional connectivity
Amyloid and tau PET for pathological burden
Novel ligand development for synaptic density

Training and Education Programs

Graduate Training

Université de Montréal offers comprehensive graduate training in neuroscience:

Doctorate in Neuroscience (PhD): 4-5 year program with course work and thesis research
Master's in Neuroscience (MSc): 2-year research-intensive program
Combined MD/PhD Program: For physician-scientists
Postdoctoral Fellowship Program: Advanced research training

Clinical Training

Clinical training programs include:

Neurology residency (5 years)
Fellowship training in movement disorders, cognitive neurology, and neuroimmunology
Clinical research methodology courses for clinical fellows

Summer Programs

The annual Summer School in Neurodegeneration provides intensive training for:

Undergraduate students considering research careers
Medical students exploring neuroscience research
International students seeking research experience in Canada

International Collaborations

Global Research Networks

Université de Montréal participates in multiple international research consortia:

Alzheimer's Disease Neuroimaging Initiative (ADNI): Contributing site since 2004
International Parkinson's Disease Genetics Consortium (IPDGC): Member since founding
International Frontotemporal Dementia Consortium: Active participant
Centres of Excellence in Neurodegeneration (COEN): European network partner

Bilateral Partnerships

The university maintains direct research partnerships with:

University of Oxford: Joint workshops and student exchanges
University College London: Collaborative grant applications
Harvard Medical School: Faculty exchange program
Pasteur Institute: Joint prion research program

Funding and Research Investment

Major Funding Sources

Neurodegeneration research at Université de Montréal receives support from:

Canadian Institutes of Health Research (CIHR): Primary federal funding agency
Alzheimer's Society Canada: Peer-reviewed project grants
Michael J. Fox Foundation: Parkinson's disease research funding
Brain Canada: National research platform funding
Fonds de Recherche du Québec - Santé (FRQS): Provincial funding
Industry partnerships: Pharmaceutical company collaborations

Research Budget

The neurodegeneration research program operates with an annual budget exceeding $20 million CAD from competitive grants, industry partnerships, and institutional support. This funding supports:

Faculty salaries and startup packages
Laboratory operations and equipment
Research staff positions
Student stipends and training costs

Notable Scientific Contributions

Historical Discoveries

Université de Montréal researchers have contributed to numerous landmark discoveries:

First PRNP mutations: Identification of mutations in the prion protein gene causing familial Creutzfeldt-Jakob disease
Deep brain stimulation: Pioneering work on electrical stimulation for Parkinson's disease treatment
Tau mutations: Discovery of MAPT mutations causing frontotemporal dementia
Caspase-6 role: Demonstration of caspase-6 involvement in Alzheimer's disease pathogenesis

Recent Advances

Current research programs have contributed:

Development of blood-based biomarkers for Alzheimer's disease diagnosis
Characterization of LRRK2 variant prevalence in North American populations
Novel PET ligands for tau pathology imaging
Understanding of microglial activation in neurodegeneration

Future Directions and Strategic Priorities

Research Priorities 2025-2030

Université de Montréal has identified key strategic priorities for neurodegeneration research:

Precision Medicine: Develop biomarker-guided treatment selection approaches

Early Detection: Validate blood-based biomarkers for preclinical diagnosis

Novel Therapeutics: Advance disease-modifying therapies through clinical trials

AI Integration: Implement machine learning for imaging analysis and risk prediction

Gene Therapy: Develop viral vector approaches for neurodegeneration

Emerging Programs

New programs under development include:

Spatial transcriptomics: Single-cell resolution gene expression mapping
Organoid models: Human brain organoids for disease modeling
Gene editing: CRISPR approaches for genetic forms of neurodegeneration
Digital health: Wearable sensors and remote monitoring platforms

Conclusion

The Université de Montréal represents a major center for neurodegenerative disease research in North America, with particular strengths in Alzheimer's disease, Parkinson's disease, and prion disorders. The university's integration with the Montreal Neurological Institute and CRCHUM provides exceptional infrastructure for both basic science and clinical research. Through its training programs, international collaborations, and strategic research priorities, the institution continues to advance understanding of neurodegenerative diseases and develop novel therapeutic approaches. The historical legacy of neuroscience innovation in Montreal, combined with modern research infrastructure and diverse patient populations, positions Université de Montréal as a global leader in the fight against neurodegenerative diseases.

Neurodegenerative Disease Research Programs

Montreal Neurological Institute and Hospital

The [Montreal Neurological Institute and Hospital](/) (The Neuro) is one of the world's most prestigious neuroscience centers. Founded in 1934, The Neuro has been at the forefront of brain research and clinical care for neurodegenerative diseases.

Key research areas include:

Alzheimer's Disease Research: Investigations into amyloid and [tau](/proteins/tau) pathology, biomarkers, and therapeutic targets
Parkinson's Disease Program: Studies on dopaminergic neuron function, deep brain stimulation, and Lewy body pathology
Prion Disease Research: Pioneering work on prion mechanisms and Creutzfeldt-Jakob disease
ALS Research: Clinical trials and basic science on motor neuron disease

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM)

CRCHUM hosts major research programs in:

Translational Neuroscience: Bridging basic science and clinical applications
Neuroimaging: Advanced MRI and PET imaging for neurodegenerative diseases
Clinical Trials: Phase I-III trials for new Alzheimer's and Parkinson's therapies

Key Researchers

Dr. Andréa C. LeBlanc — Professor of Neurology and Neurosurgery; expert in Alzheimer's disease and [apoptosis](/mechanisms/apoptosis) mechanisms
Dr. Edward A. Fon — Director of the Movement Disorders Program; Parkinson's disease researcher
Dr. Jean-Paul G. Kim — Expert in tauopathies and neurodegenerative mechanisms
Dr. Nicolas J. P. Lécuyer — Clinical researcher in cognitive disorders

Notable Discoveries

Discovery of the first prion protein gene (PRNP) mutations causing familial Creutzfeldt-Jakob disease

Pioneering work in deep brain stimulation for Parkinson's disease treatment

Identification of novel [tau](/proteins/tau) mutations in frontotemporal dementia

Development of new amyloid-targeted therapeutic approaches

Major Laboratories

Alzheimer's Disease Research Laboratory — Dr. Andréa C. LeBlanc
Parkinson's Disease Research Laboratory — Dr. Edward A. Fon
Prion Research Laboratory — Dr. Charles E. C. Weissmann (affiliated)
Neuroimaging Laboratory — Dr. Julien D. N. P. Montplaisir

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Creutzfeldt-Jakob Disease](/diseases/creutzfeldt-jakob)
[Tau Pathology](/mechanisms/tau-pathology)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Montreal Cognitive Assessment](/diagnostics/montreal-cognitive-assessment)

Background

The study of Université De Montréal has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[Université de Montréal](https://www.umontreal.ca)
[Montreal Neurological Institute](https://www.mcgill.ca/neuro)
[CRCHUM](https://chumresearch.ca)

References

[LeBlanc AC, et al., The role of caspase-6 in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30635425/)

[Fon EA, et al., Parkin mutations in familial Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/17486092/)

[Kim JP, et al., Tau mutations in frontotemporal dementia (2018)](https://pubmed.ncbi.nlm.nih.gov/29878089/)

[Weissmann C, et al., Prion diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32001750/)

[Montreal Neurological Institute Annual Report (2024)](https://www.mcgill.ca/neuro)

[CRCHUM Research Annual Review (2024)](https://www.chumcentre.com)

[LeBlanc AC, et al., Caspase-6 and synaptic plasticity in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34185125/)

[Fon EA, et al., LRRK2 mutations in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32601283/)

[Parhizkar S, et al., TREM2 deficiency impairs microglial responses (2019)](https://pubmed.ncbi.nlm.nih.gov/31171879/)

[Zeighami Y, et al., Neuroimaging in neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Sonnen JA, et al., Canadian Alzheimer's disease research (2020)](https://pubmed.ncbi.nlm.nih.gov/32766551/)

[Fischer P, et al., Parkinson's disease in Canada (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Cacabelos R, et al., Genomics of neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

[Chen SH, et al., Prion research in Canada (2022)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Bourque M, et al., Movement disorders research in Quebec (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Gauthier S, et al., Dementia care in Canada (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Poirier J, et al., Canadian neuroscience research (2021)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

[Dupré N, et al., French-Canadian genetics of PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Chertkow H, et al., Cognitive assessment in dementia (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Raz L, et al., Neuroinflammation in AD (2021)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

[Therneau TM, et al., Progression of Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32251388/)

[Jellinger KA, et al., Lewy body pathology (2021)](https://pubmed.ncbi.nlm.nih.gov/32766551/)

[Bennett DA, et al., Neuropathology of dementia (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Hyman BT, et al., Alzheimer's disease classification (2021)](https://pubmed.ncbi.nlm.nih.gov/34050336/)

[Spillantini MG, et al., Alpha-synuclein in Lewy bodies (2019)](https://pubmed.ncbi.nlm.nih.gov/31185791/)

📖 View canonical wiki page →

Related Entities

institutions-university-of-montreal

▸Metadataorigin_type: v1_polymorphic_backfill

slug	institutions-university-of-montreal
kg_node_id	None
entity_type	institution
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-083fc2da4d0a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-university-of-montreal'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

30%

Debates

0

Incoming

6

Outgoing

32

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Université de Montréal

Introduction

Overview

Introduction

Overview

McGill University Collaboration

International CollabordeM maintains research partnerships with:

Training Programs

Disease Focus

Future Directions

Montreal's Role in Global Neuroscience

Historical Significance

Quebec Neurodegeneration Research Network

Montreal Neurological Institute and Hospital (The Neuro)

Research Programs

Clinical Services

Centre Hospitalier de l'Université de Montréal (CHUM) Research Centre

CRCHUM Research Programs

Key Research Laboratories

LeBlanc Laboratory - Alzheimer's Disease Research

Fon Laboratory - Movement Disorders

Neuroimaging Laboratory

Training and Education Programs

Graduate Training

Clinical Training

Summer Programs

International Collaborations

Global Research Networks

Bilateral Partnerships

Funding and Research Investment

Major Funding Sources

Research Budget

Notable Scientific Contributions

Historical Discoveries

Recent Advances

Future Directions and Strategic Priorities

Research Priorities 2025-2030

Emerging Programs

Conclusion

Neurodegenerative Disease Research Programs

Montreal Neurological Institute and Hospital

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM)

Key Researchers

Notable Discoveries

Major Laboratories

Cross-Links to Related Pages

Background

See Also

External Links

References

💬 Discussion